Response to Ixekizumab by C-reactive Protein Level in Patients With Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naive) and COAST-W (TNF- alpha Inhibitor-Experienced) Trials at 52 Weeks

被引：0

作者：

Reveille, John ^{[1
]}

Rahman, Proton ^{[2
]}

Sandoval, David ^{[3
]}

Muram, Talia ^{[3
]}

Kronbergs, Andris ^{[3
]}

Bolce, Rebecca ^{[3
]}

Geneus, Vladimir ^{[3
]}

Hunter, Theresa ^{[3
]}

Liu-Leage, Soyi ^{[3
]}

Rudwaleit, Martin ^{[4
]}

Maldonado-Cocco, Jose ^{[5
]}

van den Bosch, Filip ^{[6
]}

机构：

[1] Univ Texas, Dept Internal Med, Houston, TX USA

[2] Mem Univ Newfoundland, St John, NF, Canada

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Klinikum Bielefeld, Dept Internal Med & Rheumatol, Bielefeld, Germany

[5] Univ Buenos Aires, Buenos Aires, DF, Argentina

[6] Ghent Univ Hosp, Ghent, Belgium

来源：

JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1121 / 1121

页数：1

共 17 条

[1] Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naive) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks
Reveille, John
Rahman, Proton
Sandoval, David
Muran, Talia
Kronbergs, Andris
Bolce, Rebecca
Geneus, Vladimir
Hunter, Theresa
Liu-Leage, Soyi
Rudwaleit, Martin
Maldonado-Cocco, Jose
Van den Bosch, Filip
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[2] RESPONSE TO IXEKIZUMAB BY C-REACTIVE PROTEIN LEVEL IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST-V (BIOLOGICAL-NAIVE) AND COAST-W (TNF-A INHIBITOR-EXPERIENCED) TRIALS AT 52 WEEKS
Chaudhury, Koyel
Rahman, Proton
Sandoval, David
Muram, Talia
Kronbergs, Andris
Bolce, Rebecca
Geneus, Vladimir
Hunter, Theresa
Liu-Leage, Soyi
Rudwaleit, Martin
Maldonado-Cocco, Jose
van den Bosch, Filip
Robinson, Philip
[J]. INTERNAL MEDICINE JOURNAL, 2021, 51 : 34 - 35
[3] RESPONSE TO IXEKIZUMAB BY C-REACTIVE PROTEIN LEVEL IN PATIENTS WITH AADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST-V (BIOLOGICAL-NAIVE) AND COAST-W (TNF-α INHIBITOR-EXPERIENCED) TRIALS AT 52 WEEKS
Reveille, John D.
Rahman, Proton
Calderon, David M. Sandoval
Muram, Talia
Kronbergs, Andris
Bolce, Rebecca
Geneus, Vladimir
Hunter, Theresa
Liu-Leage, Soyi
Rudwaleit, Martin
Maldonado-Cocco, Jose A.
van den Bosch, Filip
[J]. RHEUMATOLOGY, 2021, 60
[4] P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naive) and COAST-W (TNF-alpha inhibitor-experienced) trials at 52 weeks
Reveille, John D.
Rahman, Proton
Calderon, David M. Sandoval
Muram, Talia
Kronbergs, Andris
Bolce, Rebecca
Geneus, Vladimir
Hunter, Theresa
Liu-Leage, Soyi
Rudwaleit, Martin
Maldonado-Cocco, Jose A.
van den Bosch, Filip
[J]. RHEUMATOLOGY, 2021, 60
[5] Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
Helena Marzo-Ortega
Philip J. Mease
Proton Rahman
Victoria Navarro-Compán
Vibeke Strand
Maxime Dougados
Bernard Combe
James Cheng-Chung Wei
Xenofon Baraliakos
Theresa Hunter
David Sandoval
Xiaoqi Li
Baojin Zhu
Louis Bessette
Atul Deodhar
[J]. Rheumatology and Therapy, 2020, 7 : 759 - 774
[6] IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
Marzo-Ortega, H.
Mease, P. J.
Rahman, P.
Navarro-Compan, V.
Strand, V.
Dougados, M.
Combe, B.
Wei, J. C. C.
Baraliakos, X.
Hunter, T.
Sandoval, D.
Li, X.
Zhu, B.
Bessette, L.
Deodhar, A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 429 - 430
[7] Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
Marzo-Ortega, Helena
Mease, Philip J.
Rahman, Proton
Navarro-Compan, Victoria
Strand, Vibeke
Dougados, Maxime
Combe, Bernard
Wei, James Cheng-Chung
Baraliakos, Xenofon
Hunter, Theresa
Sandoval, David
Li, Xiaoqi
Zhu, Baojin
Bessette, Louis
Deodhar, Atul
[J]. RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 759 - 774
[8] Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Dougados, Maxime
Wei, James Cheng-Chung
Landewe, Robert
Sieper, Joachim
Baraliakos, Xenofon
Van den Bosch, Filip
Maksymowych, Walter P.
Ermann, Joerg
Walsh, Jessica A.
Tomita, Tetsuya
Deodhar, Atul
van der Heijde, Desiree
Li, Xiaoqi
Zhao, Fangyi
Bertram, Clinton C.
Gallo, Gaia
Carlier, Hilde
Gensler, Lianne S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02) : 176 - 185
[9] IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
Maksymowych, Walter P.
Gallo, Gaia
Bolce, Rebecca
Zhao, Fangyi
Geneus, Vladimir
Ostergaard, Mikkel
Tada, Kurisu
Deodhar, Atul
Gensler, Lianne S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 884 - 885
[10] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
Boonen, Annelies
Dougados, Maxime
Combe, Bernard
Hunter, Theresa
Zhu, Baojin
Sandoval, David
Bessette, Louis
Deodhar, Atul
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 197 - 198

← 1 2 →